Free Trial

Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Oruka Therapeutics logo
$10.95 -0.24 (-2.14%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$10.53 -0.42 (-3.84%)
As of 05/23/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oruka Therapeutics Stock (NASDAQ:ORKA)

Key Stats

Today's Range
$10.70
$11.22
50-Day Range
$6.78
$12.50
52-Week Range
$5.49
$31.13
Volume
135,502 shs
Average Volume
225,915 shs
Market Capitalization
$409.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.38
Consensus Rating
Buy

Company Overview

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ORKA MarketRank™: 

Oruka Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 561st out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oruka Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Oruka Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oruka Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oruka Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Oruka Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ORKA.
  • Dividend Yield

    Oruka Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oruka Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ORKA.
  • News Sentiment

    Oruka Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.67% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oruka Therapeutics' insider trading history.
Receive ORKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORKA Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Wedbush Predicts Weaker Earnings for Oruka Therapeutics
TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)
See More Headlines

ORKA Stock Analysis - Frequently Asked Questions

Oruka Therapeutics' stock was trading at $19.39 on January 1st, 2025. Since then, ORKA shares have decreased by 43.5% and is now trading at $10.95.
View the best growth stocks for 2025 here
.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17.

Top institutional investors of Oruka Therapeutics include Braidwell LP (4.20%), Affinity Asset Advisors LLC (1.46%), Jefferies Financial Group Inc. (1.08%) and Redmile Group LLC (1.03%).
View institutional ownership trends
.

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and Skye Bioscience (SKYE).

Company Calendar

Last Earnings
5/14/2025
Today
5/25/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORKA
Previous Symbol
NASDAQ:ORKA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.38
High Stock Price Target
$49.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+268.7%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
27,065,000
Market Cap
$409.98 million
Optionable
N/A
Beta
0.25
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ORKA) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners